Cyclerion Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing total revenues of $875,000, a significant increase from $194,000 in the same period last year. This growth was primarily driven by a new purchase agreement with Akebia Therapeutics, which contributed $800,000 in revenue. The company also recognized $75,000 from an option agreement, although this was a decrease from $194,000 in the prior year. For the nine months ending September 30, 2025, total revenues reached $1.049 million, compared to $194,000 for the same period in 2024.
In terms of expenses, Cyclerion's total costs rose to $1.881 million for the third quarter, up from $1.322 million in the previous year, marking a 42% increase. Research and development expenses surged to $348,000, a substantial rise from $81,000 in Q3 2024, reflecting the company's intensified focus on its product pipeline, particularly in treatment-resistant depression (TRD). General and administrative expenses also increased to $1.533 million, up from $1.241 million, driven by higher professional consulting and legal fees. The net loss for the quarter was $976,000, compared to a loss of $723,000 in Q3 2024.
Cyclerion's operational strategy has shifted towards developing therapeutics for neuropsychiatric diseases, with TRD as a key focus. The company entered a license agreement with the Massachusetts Institute of Technology (MIT) in September 2025, granting it exclusive rights to develop products for treating neuropsychiatric disorders. This agreement is expected to enhance Cyclerion's product offerings and market position. Additionally, the company is exploring licensing opportunities for its olinciguat technology after terminating a previous option agreement due to unsuccessful negotiations.
As of September 30, 2025, Cyclerion reported cash and cash equivalents of $4.568 million, an increase from $3.232 million at the end of 2024. The company has indicated that this cash is expected to fund operations into the second quarter of 2026, although it will need to secure additional funding to sustain operations beyond that period. Cyclerion's management has acknowledged substantial doubt regarding its ability to continue as a going concern, emphasizing the need for further capital to support ongoing losses and operational needs.
Looking ahead, Cyclerion plans to continue its focus on TRD and other neuropsychiatric conditions while managing its expenses and seeking additional funding sources. The company has initiated an at-the-market offering program to raise capital and is actively pursuing strategic partnerships to enhance its product pipeline and financial stability.
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics focuses on developing novel therapeutics for neuropsychiatric and serious diseases, primarily targeting treatment-resistant depression (TRD). The company leverages its legacy soluble guanylate cyclase (sGC) assets through licensing and out-licensing agreements, aiming to generate revenue for pipeline development. It emphasizes intellectual property protection, regulatory compliance, and strategic partnerships to advance innovative treatments in high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.